Targeting the PD-1/PD-L1 checkpoint, one modality of checkpoint blockade immunotherapy (CPI), has been an established treatment for many cancers and has impacted the life expectancy and clinical outcome of many patients. The gene discussed is CD274; the disease is cancer.